NDA 020873 · Sandoz
Angiomax
Bivalirudin · Intravenous · Anti-coagulant; Direct Thrombin Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jul 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Dec 15, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
74
21 Phase 3, 6 recruiting
FAERS reports
992
906 serious, 155 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2025.
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).( 1 )
Mechanism: Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework, which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. The...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 30, 2005 Supplement 11 · Efficacy LetterLabel
- Jun 13, 2005 Supplement 6 · Efficacy Letter
- Dec 15, 2000 Original approval · Type 1 - New Molecular Entity NovelPediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Written Request
1 products under this application
- ANGIOMAX · BIVALIRUDIN 250MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Bivalirudin" as an intervention, any sponsor and status, largest first.
- Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093158 · 13,800 participants · Start Aug 2003
Drug: Angiomax (bivalirudin) anticoagulant · For: Unstable Angina; Myocardial Infarction; Acute Disease
Sites: New York, New York
- Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCIPivotal-lookingCompleted
Shenyang Northern HospitalAcademic, hospital or other
NCT03822975 · 6,016 participants · Start Feb 14, 2019 · Primary completion May 7, 2022
Drug: Bivalirudin; unfractionated Heparin · For: ST Elevation Myocardial Infarction
Sites: Bengbu, China; Fuyang, China; Haozhou, China · 85 sites in all
- Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEARTPivotal-lookingCompleted
Uppsala UniversityAcademic, hospital or other
NCT02311231 · 6,012 participants · Start Jun 2014 · Primary completion Mar 2017
Drug: bivalirudin; Heparin · For: ST-segment Elevation Myocardial Infarction; Non ST-segment Elevation Myocardial Infarction
Sites: Lund, Sweden
- Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary SyndromesPivotal-lookingNot yet recruiting
Shenyang Northern HospitalAcademic, hospital or other
NCT07383155 · 5,270 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 31, 2027
Drug: Anticoagulant Therapy · For: Percutaneous Coronary Intervention; High Bleeding Risk; Acute Coronary Syndromes and 1 more
- Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)Pivotal-lookingCompleted
Deutsches Herzzentrum MuenchenAcademic, hospital or other
NCT00262054 · 4,570 participants · Start Nov 2005 · Primary completion Feb 2008
Drug: Bivalirudin; Un-fractionated heparin · For: Coronary Disease; Angina Pectoris
Sites: Bad Krozingen, Germany; Bad Segeberg, Germany; Munich, Germany · 4 sites in all
- Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial InfarctionPivotal-lookingCompleted
Cardiovascular Research Foundation, New YorkAcademic, hospital or other
NCT00433966 · 3,602 participants · Start Mar 2005 · Primary completion Jun 2008
Drug: Bivalirudin; Unfractionated heparin · For: Myocardial Infarction
Sites: Greensboro, North Carolina
- A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCIPivotal-lookingTerminated
Regado Biosciences, Inc.Industry
NCT01848106 · 3,232 participants · Start Sep 2013 · Primary completion Aug 2014
Drug: pegnivacogin/anivamersen; Bivalirudin · For: Coronary Artery Disease
Sites: Rapid City, South Dakota
- Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCIPivotal-lookingCompleted
Beijing Anzhen HospitalAcademic, hospital or other
NCT03664180 · 2,989 participants · Start Jan 11, 2019 · Primary completion Nov 23, 2022
Drug: Bivalirudin; Enoxaparin and 4 more · For: STEMI - ST Elevation Myocardial Infarction
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective200
- off label use114
- haemorrhage91
- heparin-induced thrombocytopenia76
- gastrointestinal haemorrhage45
- thrombosis44
- vascular stent thrombosis40
- acute myocardial infarction36
- hypotension33
- thrombosis in device33
- product use issue29
- cardiac arrest25
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 17 |
| 2006 | 17 |
| 2007 | 7 |
| 2008 | 13 |
| 2009 | 23 |
| 2010 | 24 |
| 2011 | 22 |
| 2012 | 29 |
| 2013 | 31 |
| 2014 | 46 |
| 2015 | 27 |
| 2016 | 32 |
| 2017 | 26 |
| 2018 | 29 |
| 2019 | 47 |
| 2020 | 65 |
| 2021 | 84 |
| 2022 | 93 |
| 2023 | 93 |
| 2024 | 100 |
| 2025 | 91 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Angiomax* (Bivalirudin*) · HCPCS J0583
2024 spending
$781
Beneficiaries
15
16 claims
Per beneficiary
$52
2024 ASP limit $0.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,430 |
| 2021 | $14,094 |
| 2022 | $10,757 |
| 2023 | $3,810 |
| 2024 | $781 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.
McMichael A, Weller J, Li X, et al. · Pediatr Crit Care Med 2025 · Randomized Controlled Trial, Comparative Study
- Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.
Stone GW, Valgimigli M, Erlinge D, et al. · J Am Coll Cardiol 2024 · Meta-Analysis, Comparative Study
- Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation.
Huang D, Guan Q, Qin J, et al. · Perfusion 2023 · Meta-Analysis
- Anticoagulation in Acute Coronary Syndrome-State of the Art.
Zeitouni M, Kerneis M, Nafee T, et al. · Prog Cardiovasc Dis 2018 · Systematic Review
- Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation.
Hasegawa D, Sato R, Prasitlumkum N, et al. · ASAIO J 2023 · Systematic Review, Meta-Analysis
- Heparin-induced Thrombocytopenia in Pediatrics Following Cardiopulmonary Bypass.
Yuan SM · J Coll Physicians Surg Pak 2019 · Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.